Physician profile
Joseph Ragno
NPI 1952390767
$3,544.16
in general payments reported to CMS, 2019-2025
34 companies · $741 in 2025
The $741 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $582 · 2020: $210 · 2021: $29.71 · 2022: $404 · 2023: $603 · 2024: $974 · 2025: $741.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,317.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,317.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $640.89 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Exact Sciences Corporation | $360.44 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lilly USA, LLC | $343.44 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $272.48 | 2022-2024 | |
| Glaxosmithkline, LLC. | $265.04 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Pfizer INC. | $231.78 | 2019-2025 | |
| Abbvie INC. | $201.99 | 2019-2025 | |
| Amgen INC. | $180.86 | 2019-2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $120.64 | 2019-2020 | |
| Novo Nordisk INC | $108.61 | 2019-2025 | Wegovy |
| Phathom Pharmaceuticals, INC. | $108.54 | 2024 | Voquezna |
| Merck Sharp & Dohme LLC | $108.25 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Janssen Pharmaceuticals, INC | $83.28 | 2019-2024 | Spravato |
| Astellas Pharma US INC | $55.23 | 2023-2025 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $46.40 | 2019-2023 | Xifaxan |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $40.32 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $39.56 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $29.71 | 2021 | |
| Allergan, INC. | $27.58 | 2020 | |
| Axsome Therapeutics, INC. | $27.24 | 2025 | Symbravo |
| Almatica Pharma LLC | $24.22 | 2024 | Loreev Xr |
| Seqirus USA INC | $23.63 | 2025 | Flucelvax |
| Teleflex LLC | $22.71 | 2025 | Barrigel |
| Corcept Therapeutics | $22.00 | 2025 | Korlym |
| Genentech USA, INC. | $20.87 | 2020 | |
| Dynavax Technologies Corporation | $20.74 | 2025 | Heplisav-B |
| Therapeuticsmd, INC. | $18.87 | 2019 | |
| Abbott Laboratories | $17.30 | 2024 | Proclaim |
| Medtronic Vascular, INC. | $15.99 | 2019 | |
| Sanofi Pasteur INC. | $15.87 | 2020 | |
| Axonics, INC. | $13.53 | 2024 | Axonics |
| Phadia US INC. | $12.48 | 2022 | |
| Horizon Therapeutics Plc | $12.17 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Ragno listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.